$KRYS insider trading
Over the last 12 months, Krystal Biotech insiders reported no purchases and 37 sales totaling $87.3M across SEC Form 4 filings. 95% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $87.3M 37 events
- Events · 12m
- 37 Form 4 filings, grouped
- Insiders · 12m
- 6 distinct reporters
- 10b5-1 share
- 95% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | ROSSI DINO AD | ▼ Sale | 25,000 | $329.12 | $8.2M | -33.3% | 8 tranches |
| Jun 25, 2026 | Thomas John CharlesEVP, General Counsel · O | ▼ Sale | 1,000 | $347.27 | $347K | -100% | plan |
| Jun 4, 2026 | Krishnan SumaPresident, R&D · O·D·10% | ▼ Sale | 240 | $311.65 | $75K | — | plan |
| Jun 4, 2026 | Krishnan SumaPresident, R&D · O·D·10% | ▼ Sale | 2,039 | $310.94 | $634K | -0.1% | plan |
| Jun 4, 2026 | Krishnan SumaPresident, R&D · O·D·10% | ▼ Sale | 2,801 | $309.95 | $868K | -0.2% | plan |
| Jun 4, 2026 | Krishnan SumaPresident, R&D · O·D·10% | ▼ Sale | 3,803 | $308.89 | $1.2M | -0.3% | plan |
| Jun 4, 2026 | Krishnan SumaPresident, R&D · O·D·10% | ▼ Sale | 12,729 | $307.81 | $3.9M | -0.9% | plan |
| Jun 4, 2026 | Krishnan SumaPresident, R&D · O·D·10% | ▼ Sale | 1,348 | $307.09 | $414K | -0.1% | plan |
| Jun 4, 2026 | Krishnan SumaPresident, R&D · O·D·10% | ▼ Sale | 480 | $305.86 | $147K | — | plan |
| Jun 4, 2026 | Krishnan SumaPresident, R&D · O·D·10% | ▼ Sale | 400 | $304.89 | $122K | — | plan |
| Jun 4, 2026 | Krishnan SumaPresident, R&D · O·D·10% | ▼ Sale | 247 | $303.17 | $75K | — | plan |
| Jun 4, 2026 | Krishnan SumaPresident, R&D · O·D·10% | ▼ Sale | 593 | $302.25 | $179K | — | plan |
| Jun 4, 2026 | Krishnan SumaPresident, R&D · O·D·10% | ▼ Sale | 320 | $300.75 | $96K | — | plan |
| Jun 4, 2026 | Krishnan Krish SPresident and CEO · O·D·10% | ▼ Sale | 40 | $312.23 | $12K | — | plan |
| Jun 4, 2026 | Krishnan Krish SPresident and CEO · O·D·10% | ▼ Sale | 964 | $311.36 | $300K | -0.1% | plan |
| Jun 4, 2026 | Krishnan Krish SPresident and CEO · O·D·10% | ▼ Sale | 2,652 | $310.43 | $823K | -0.2% | plan |
| Jun 4, 2026 | Krishnan Krish SPresident and CEO · O·D·10% | ▼ Sale | 2,784 | $309.49 | $862K | -0.2% | plan |
| Jun 4, 2026 | Krishnan Krish SPresident and CEO · O·D·10% | ▼ Sale | 4,830 | $308.47 | $1.5M | -0.3% | plan |
| Jun 4, 2026 | Krishnan Krish SPresident and CEO · O·D·10% | ▼ Sale | 11,461 | $307.68 | $3.5M | -0.8% | plan |
| Jun 4, 2026 | Krishnan Krish SPresident and CEO · O·D·10% | ▼ Sale | 589 | $306.33 | $180K | — | plan |
| Jun 4, 2026 | Krishnan Krish SPresident and CEO · O·D·10% | ▼ Sale | 544 | $304.81 | $166K | — | plan |
| Jun 4, 2026 | Krishnan Krish SPresident and CEO · O·D·10% | ▼ Sale | 176 | $303.17 | $53K | — | plan |
| Jun 4, 2026 | Krishnan Krish SPresident and CEO · O·D·10% | ▼ Sale | 640 | $302.24 | $193K | — | plan |
| Jun 4, 2026 | Krishnan Krish SPresident and CEO · O·D·10% | ▼ Sale | 320 | $300.75 | $96K | — | plan |
| May 26, 2026 | Thomas John CharlesEVP, General Counsel · O | ▼ Sale | 642 | $302.03 | $194K | -100% | plan |
| Mar 4, 2026 | Krishnan SumaPresident, R&D · O·D·10% | ▼ Sale | 25,000 | $263.21 | $6.6M | -1.8% | plan · 10 tranches |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO · O·D·10% | ▼ Sale | 25,000 | $263.17 | $6.6M | -1.7% | plan · 10 tranches |
| Mar 2, 2026 | ROMANO KATHRYNChief Accounting Officer · O | ▼ Sale | 750 | $267.6 | $201K | -3.2% | plan |
| Feb 27, 2026 | JANNEY DANIELD | ▼ Sale | 11,803 | $275.59 | $3.3M | -13.9% | plan · 2 tranches · indirect |
| Feb 26, 2026 | JANNEY DANIELD | ▼ Sale | 22,266 | $271.09 | $6.0M | -20.7% | plan · 11 tranches · indirect |
| Feb 24, 2026 | JANNEY DANIELD | ▼ Sale | 37,895 | $266.88 | $10.1M | -100% | plan · 9 tranches |
| Feb 19, 2026 | ROSSI DINO AD | ▼ Sale | 18,950 | $261.41 | $5.0M | -19.4% | 2 tranches |
| Feb 9, 2026 | ROMANO KATHRYNChief Accounting Officer · O | ▼ Sale | 12,500 | $272.14 | $3.4M | -39.3% | plan · 7 tranches |
| Dec 4, 2025 | Krishnan SumaPresident, R&D · O·D·10% | ▼ Sale | 25,000 | $220.14 | $5.5M | -1.7% | plan · 8 tranches · indirect |
| Dec 4, 2025 | Krishnan SumaPresident, R&D · O·D·10% | ▼ Sale | 25,000 | $220.16 | $5.5M | -1.7% | plan · 8 tranches |
| Dec 4, 2025 | Krishnan Krish SPresident and CEO · O·D·10% | ▼ Sale | 25,000 | $220.16 | $5.5M | -1.7% | plan · 8 tranches · indirect |
| Dec 4, 2025 | Krishnan Krish SPresident and CEO · O·D·10% | ▼ Sale | 25,000 | $220.14 | $5.5M | -1.7% | plan · 8 tranches |
Every $KRYS filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Krystal Biotech filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $KRYS feed.